October 29, 2020

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

PARP inhibition is an effective treatment for patients with MBC and gPALB2 or sBRCA1/2 mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond gBRCA1/2 mutation carriers. These results emphasize the value of molecular characterization for treatment decisions in MBC.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Tung et al. (Thu,) studied this question.

synapsesocial.com/papers/69d7e9bf05ee2ba81dbee86e https://doi.org/https://doi.org/10.1200/jco.20.02151

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Optimal two-stage designs for phase II clinical trials1989 · 3,642 citations
2Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer2010 · 984 citations
3Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases2000 · 602 citations
4Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA)2012 · 671 citations
5Breast-Cancer Risk in Families with Mutations in PALB22014 · 855 citations

Preguntar a la IA

Me gusta

Guardar